Skip to main
PDSB

PDSB Stock Forecast & Price Target

PDSB Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PDS Biotechnology is currently facing financing and dilution risks as it seeks to advance its lead program, PDS0301, in a randomized Phase 2b study for metastatic colorectal cancer (mCRC). The company recently announced a strategic shift to focus on PDS0301 as its lead program, while seeking a commercial partner or external funding for its Phase 3 study of PDS0101 in HPV16-positive head and neck cancer. With strong response and survival signals in the NCI experience, PDS0301 shows promising potential in a difficult-to-treat mCRC population, but its success in a randomized setting remains to be seen. Additionally, the company's decision to seek a partner for PDS0101 could help preserve its value in a competitive market. However, the company's depressed equity value may pose challenges in securing adequate funding.

Bears say

PDS Biotechnology is a high-risk stock due to its limited financial resources and focus on early-stage and late-stage cancer treatments with unproven success. The recent workforce reduction, while necessary to conserve funds, may impede the company's ability to advance its pipeline. The potential for partnerships and positive clinical trial data could positively impact the company's valuation, but failure to achieve these milestones could lead to a significant decline in the stock.

PDSB has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PDS Biotechnology Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PDS Biotechnology Corporation (PDSB) Forecast

Analysts have given PDSB a Strong Buy based on their latest research and market trends.

According to 2 analysts, PDSB has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PDS Biotechnology Corporation (PDSB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.